Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy
Public ClinicalTrials.gov record NCT02680184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Two Part Open-Label, Phase 1B Clinical Study of CMP-001 Administered Either in Combination With Pembrolizumab or as a Monotherapy in Subjects With Advanced Melanoma
Study identification
- NCT ID
- NCT02680184
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 199 participants
Conditions and interventions
Conditions
Interventions
- CMP-001 Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 11, 2016
- Primary completion
- Dec 5, 2022
- Completion
- Dec 5, 2022
- Last update posted
- Jul 3, 2025
2016 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Phoenix | Arizona | 85006 | — |
| University of Arizona | Tucson | Arizona | 85721 | — |
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94115 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| Georgetown | Washington D.C. | District of Columbia | 02007 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15213 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02680184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 3, 2025 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02680184 live on ClinicalTrials.gov.